Jan 8, 2022, 1:20 AM ETInterview, Conference Presentation

E62: Elizabeth Holmes verdict, fraud origins & takeaways, navigating "The Great Markdown" & more

Elizabeth Holmes was found guilty on four counts of fraud: two counts of wire fraud and two counts of conspiracy to commit fraud.
The remaining seven of her original eleven charges resulted in either not guilty verdicts (four) or a split verdict where the jury could not reach unanimity (three).
Sentencing faces up to 20 years per count, though concurrent service and potential 15% sentence reductions for good behavior could result in a 4 to 10-year term.
The jury specifically found that Holmes defrauded investors regarding:
- A fraudulent partnership with Pfizer, where she displayed a logo without technology validation.
- False claims that the U.S. military was a customer, which was used to secure support and contracts.
- A misleading deal with Walgreens and Safeway, where investors treated the contracts as an endorsement of the technology's viability.
Prosecutors did not call Silicon Valley venture firms (like Sequoia or GV) to testify regarding why they declined to invest; the hosts argued this strategy would not have strengthened the fraud case since the core issue was active misrepresentation to those who did invest, not the lack of investment from others.
The legal strategy highlighted that Holmes was convicted for lying about the current state of the business (e.g., customer logos, product capabilities) rather than failing to meet future "messianic" vision claims.

Life science expert Chris Sacca and bio-entrepreneur Freeberg discussed the physical limitations of Holmes' "one drop of blood" claim.
Current microfluidics and CRISPR technologies allow for precise assays in picoliter volumes, making single-molecule detection theoretically possible for specific large molecules like cholesterol.
However, the consensus is that running hundreds of distinct assays simultaneously from a single drop is not currently physically possible due to volume constraints and the need for statistically significant readings.
Freeberg noted that while individual tests (like blood sugar or lipid panels) are feasible with a drop of blood, creating a comprehensive "blood panel" equivalent to a standard hospital CBC from one drop faces significant biological and physical hurdles.
The failure of the technology was attributed to the "stacking" of multiple unproven technological assets required to achieve the promised results, rather than a lack of intelligence among the engineering teams.

The discussion identifies a "self-reinforcing cycle" where media hype regarding Holmes' narrative (young female savior, Steve Jobs-esque) suppressed necessary fact-checking by journalists and investors.
Investors outside Silicon Valley (e.g., Rupert Murdoch, DeVos family) were the primary capital sources, whereas established VC firms largely avoided the deal due to a refusal to provide due diligence access by Holmes.
Hosts argued that the lack of diligence by later-stage investors was a result of "social proof" and "signaling value" rather than independent analysis, a dynamic also observed in the Bernie Madoff scandal.
A "theranos 2.0" scenario was discussed where founders refuse to show basic financials (specifically gross revenue without asterisks), leading to failed deals due to a lack of basic fiscal transparency.
Delaware General Corporate Law Section 220 was highlighted as a powerful tool for shareholders to demand detailed books and records in private companies if malfeasance is suspected, even if the company claims information rights are restricted.

Public SaaS valuations have undergone a "major regression to the mean," with the median enterprise value relative to expected 12-month revenue dropping from ~15x in early 2021 to ~10x currently.
The market correction was triggered by the Federal Reserve's shift from "transitory" inflation narratives to hawkish statements and the release of meeting minutes that contradicted previous guidance on the timeline for rate hikes and balance sheet reduction (Quantitative Tightening).
The Fed's inconsistency in communication (announcing one rate path, then revealing a more aggressive one in minutes) is criticized for introducing massive uncertainty into the market.
Hosts predict a "great write-down" in private markets as public multiples compress, forcing 900+ unicorns to face valuations they can no longer achieve via IPO or acquisition.
Many private companies raised at valuations that would require 30-40% higher revenue to justify under new public market pricing frameworks, creating a liquidity crunch.
Potential outcomes for private unicorns include:
- "Pushes" where investors get their capital back without gain or loss (e.g., Classy acquisition by NYT).
- Down-rounds where valuations are marked down significantly, potentially wiping out equity value for earlier stakeholders.
- A shift toward lower burn multiples, where VC firms will only fund growth if the burn-to-revenue ratio is closer to 1:1 or 2:1 rather than 5:1 or 6:1.

The primary advice is to achieve "default alive" status, meaning the company generates positive contribution margins and profits before cash runs out, avoiding reliance on constant fundraising.
Founders are urged to focus on the six-step value creation rubric:
1. Can you make a product?
2. Do people want to buy it?
3. Can you make a positive gross margin?
4. Can you achieve a positive return on marketing spend (LTV > CAC)?
5. Can you scale efficiently (increasing returns as you grow)?
6. Can you transition to a platform model?
The concept of "burn multiple" is prioritized over raw growth; a burn multiple of 1.0 or less is considered excellent, while multiples above 3.0-4.0 raise red flags about product-market fit.
Founders are advised to be frugal, cutting non-essential spending (conferences, excess office space) and focusing resources strictly on product, sales, and marketing.
Raising capital at valuations significantly higher than what is reasonably deliverable in a downturn creates toxic dynamics for future rounds and investor returns.
Historical data is cited to show that even the best companies (Facebook, Google, Apple) saw growth rates slow to ~20% over 20 years, warning against business models based on perpetual 40-60% growth.

Venture capital is consolidating, with a prediction that 80% of future private capital will flow through a small number of mega-firms (e.g., Andreessen Horowitz, Tiger Global).
There is speculation that large VC firms (like Andreessen) may eventually go public to monetize their General Partner (GP) equity, a move previously unthinkable for traditional partnerships but now viable at massive Asset Under Management (AUM) scales.
The trend suggests that VC firms operating with public market valuations could generate significantly higher carry and firm value compared to the historical model of simply distributing fund profits.
Hosts note that while public markets are volatile, private markets often lag in marking down valuations, creating a "disincentive" for VCs to write down portfolios until forced by reality or exit events.

The hosts are planning the "All-In Summit," aiming to create a high-fidelity, "Davos-style" experience with a focus on networking and substance rather than just stage presentations.
A media trio concept was proposed involving Jake Howell, MrBeast, and a third guest to discuss the future of media.
The hosts emphasized the importance of high-quality production and "magical" experiences for attendees, hiring professional conference organizers to handle logistics.